Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19759343 | 0.84 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2GPR119PDK4 | |
| SCHEMBL16052667 | 0.83 | USP30 (0.40) | NR1H2USP2SMN1; SMN2GPR119PDK4 | |
| SCHEMBL16052666 | 0.83 | USP30 (0.40) | NR1H2USP2SMN1; SMN2GPR119PDK4 | |
| SCHEMBL25047623 | 0.81 | PDK4 (0.39) | NR1H2USP2SMN1; SMN2GPR119PDK4 | |
| SCHEMBL26136585 | 0.81 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2GPR119PDK4 | |
| SCHEMBL30848770 | 0.79 | USP2 (0.44) | NR1H2USP2SMN1; SMN2GPR119PDK4 | |
| SCHEMBL15785128 | 0.77 | GPR119 (0.39) | NR1H2GPR119PDK4NAMPT | |
| SCHEMBL4934988 | 0.77 | USP30 (0.46) | GPR119PDK4KDM4ENAMPTGRM5 | |
| SCHEMBL28036127 | 0.77 | USP2 (0.40) | NR1H2USP2SMN1; SMN2GPR119PDK4 | |
| SCHEMBL29178745 | 0.76 | STS (0.40) | NR1H2GPR119PDK4KDM4ENAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385036-B2 | Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10336748-B2 | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336748-B2 | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | RORC, RORB, RORA | NR1H2 13/4885USP2 3144/4885SMN1; SMN2 3331/4885 |
| US-10385036-B2 | Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof | RORC, RORB, RORA | NR1H2 21/4885USP2 2329/4885SMN1; SMN2 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.